Top Markets
#1 Islamic Coin Islamic Coin +151.61%
#2 Black Phoenix Black Phoenix +35.36%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.36%
#4 Akedo Akedo +16.92%
#5 Fake World Assets Fake World Assets +15.77%
#6 Palladium Network Palladium Network +15.41%
#7 HOME HOME +12.57%
#8 clBTC clBTC +11.81%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.75%
#10 MarsCoin MarsCoin +10.60%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Bio-Path Holdings, Inc. Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc.

BPTH
Classifica tra le azioni #39844
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on... Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Prezzo delle azioni
$0.035
Ultima sincronizzazione: 2026-08-13
Capitalizzazione di mercato
$326.98K
Variazione (1 giorno)
-12.50%
Variazione (1 anno)
-74.55%
Paese
US
Scambia Bio-Path Holdings, Inc. (BPTH)

Categoria

Healthcare
Ricavi di Bio-Path Holdings, Inc. (BPTH)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Bio-Path Holdings, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Bio-Path Holdings, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE